HC Wainwright restated their buy rating on shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in a report issued on Monday. The brokerage currently has a $1.50 target price on the stock, down from their prior target price of $4.50.
Separately, ValuEngine downgraded shares of Bio-Path Holdings from a sell rating to a strong sell rating in a report on Friday, September 1st.
Shares of Bio-Path Holdings (NASDAQ:BPTH) traded down $0.02 during midday trading on Monday, reaching $0.29. 527,800 shares of the company were exchanged, compared to its average volume of 396,460. Bio-Path Holdings has a 12-month low of $0.25 and a 12-month high of $1.50.
Bio-Path Holdings (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.02). analysts anticipate that Bio-Path Holdings will post -0.08 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of BPTH. Bank of New York Mellon Corp raised its position in Bio-Path Holdings by 1.7% during the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after acquiring an additional 5,172 shares during the period. Legal & General Group Plc raised its position in Bio-Path Holdings by 5,474.3% during the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after acquiring an additional 1,741,978 shares during the period. HighTower Advisors LLC raised its position in Bio-Path Holdings by 0.3% during the second quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after acquiring an additional 4,000 shares during the period. Finally, Sabby Management LLC raised its position in Bio-Path Holdings by 73.2% during the second quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock worth $462,000 after acquiring an additional 503,488 shares during the period. Institutional investors own 15.15% of the company’s stock.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.